Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals has informed the BSE that its insider trading window will remain closed from 1st October 2025 until 48 hours after the declaration of its unaudited financial results for the quarter ended 30th September 2025. All directors, key managerial personnel, designated persons, connected persons, insiders, and their immediate relatives are barred from trading in the company's shares during this period. The date of the board meeting to approve the Q2 FY26 results will be announced later. The intimation is signed by Managing Director Ashish Narayan Sakalkar.
This is a routine compliance disclosure ahead of the upcoming quarterly results. It does not directly affect share price but signals that Q2 FY26 results will be released soon, which investors should watch for fundamental updates.